<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                                                             International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br />  <br />                                                                             Contents lists available SciVerse ScienceDirect <br />  <br />                                                             International Journal Parasitology: <br />                                                                   Drugs Drug Resistance <br />                                                                journal homepage: www.elsevier.com/locate/ijpddr <br />  <br />  <br />  <br /> Invited review <br />  <br /> Inhibitors RNA editing potential chemotherapeutics against <br /> trypanosomatid pathogens <br /> Reza Salavati a,b,c,&#226;&#8225;&#8216;, Houtan Moshiri a,b, Smriti Kala b, Hamed Shateri Najafabadi b,c <br /> a <br />   Department Biochemistry, McGill University, McIntyre Medical Building, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada H3G1Y6 <br /> b <br />   Institute Parasitology, McGill University, 21111 Lakeshore Road, Ste. Anne Bellevue, Quebec, Canada H9X3V9 <br /> c <br />   McGill Centre Bioinformatics, McGill University, Bellini Building, 3649 Promenade Sir William Osler, Montreal, Quebec, Canada H3G0B1 <br />  <br />  <br />  <br /> a r t c l e              n f o                                        b s t r c t <br />  <br /> Article history:                                                          The related trypanosomatid pathogens, Trypanosoma brucei spp., Trypanosoma cruzi Leishmania spp. <br /> Received 16 August 2011                                                   cause devastating diseases humans animals continue pose major challenge drug devel- <br /> Received revised form 17 October 2011                                  opment. Mitochondrial RNA editing, catalyzed multi-protein complexes known editosomes, has <br /> Accepted 21 October 2011 <br />                                                                           provided opportunity development ef&#239;&#172;?cient speci&#239;&#172;?c chemotherapeutic targets try- <br /> Available online 13 November 2011 <br />                                                                           panosomatid pathogens. This review discuss methods discovery RNA editing inhibitors, as <br />                                                                           inhibitors T. brucei editosome recently discovered creative virtual <br /> Keywords: <br />                                                                           high throughput screening methods. In addition, use inhibitors agents block <br /> Trypanosomatids <br /> RNA editing inhibitor <br />                                                                           perturb steps RNA editing process discussed. These inhibitors potentially <br /> Virtual screening                                                         used study dynamic processing assembly editosome proteins. A thorough under- <br /> High-throughput screening                                                 standing mechanisms speci&#239;&#172;?cities new inhibitors needed order contribute <br />                                                                           functional studies essential gene expression mechanism possibility future <br />                                                                           drug development trypanosomatid pathogens. <br />                                                                                          &#195;&#8220; 2011 Australian Society Parasitology Published Elsevier Ltd. All rights reserved. <br />  <br />  <br />  <br />  <br /> Contents <br />  <br />     1.   Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   36 <br />     2.   RNA editing process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .        39 <br />     3.   The editosome composition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .               39 <br />     4.   Editosome drug target . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .           40 <br />     5.   High-throughput screening (HTS) methods: virtual chemical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                                        40 <br />          5.1.   Virtual screening methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                 40 <br />          5.2.   Chemical HTS methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .                41 <br />     6.   Editosome inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         43 <br />     7.   Conclusion prospects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .             44 <br />          References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   44 <br />  <br />  <br />  <br />  <br /> 1. Introduction                                                                                                           Leishmaniasis, respectively. Leishmaniasis reportedly mortal- <br />                                                                                                                           ity rate 50,000 individuals year annual loss 2.1 million <br />     The major trypanosomatid pathogens, Trypanosoma                                                                 disability-adjusted life years (DALYs), followed sleeping sick- <br /> brucei, Trypanosoma cruzi Leishmania major related para-                                                          ness 48,000 deaths year (1.5 million DALYs year) <br /> sitic protozoa kinetoplastids, cause different diseases,                                                           (WHO, 2002). Chagas disease causes 15,000 deaths loss <br /> including Human African trypanosomiasis, Chagas disease,                                                              700,000 DALYs annually. The available drugs diseases <br />                                                                                                                           ideal, toxic, costly, invasive routes <br />                                                                                                                           administration (Croft et al., 2005; Delespaux Koning, <br />  &#226;&#8225;&#8216; Corresponding author at: Institute Parasitology, McGill University, 21111 <br /> Lakeshore Road, Ste. Anne Bellevue, Quebec, Canada H9X3V9. Tel.: +1 514 398 <br />                                                                                                                           2007; Stuart et al., 2008; Teixeira et al., 2006). Also, resistance <br /> 7721; fax: +1 514 398 7857.                                                                                               drugs emerged; is <br />    E-mail address: reza.salavati@mcgill.ca (R. Salavati).                                                                 urgent need development new drugs (Buckner et al., <br />  <br /> 2211-3207/$ - matter &#195;&#8220; 2011 Australian Society Parasitology Published Elsevier Ltd. All rights reserved. <br /> doi:10.1016/j.ijpddr.2011.10.003 <br />                                       R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46                             37 <br />  <br />  <br /> 1998; den Boer Davidson, 2006; Olliaro et al., 2005; Wilkinson                        stage, procyclic form (PF) T. brucei highly active mitochon- <br /> et al., 2008).                                                                            drion (Vickerman, 1965) generates ATP oxidative phosphor- <br />    Since Rob Benne discovered RNA editing 1986 (Benne et al.,                          ylation, RNA editing crucial energy metabolism. <br /> 1986), come learn details mechanisms                            Although oxidative phosphorylation repressed bloodstream <br /> and major players involved remarkable post-transcriptional                        form (BF), RNA-editing required maintain ac- <br /> RNA maturation process, including potential effective                           tive mitochondrion, needed essential metabolic <br /> anti-trypanosomal drug target. Most mitochondrial mRNAs                                pathways calcium homeostasis fatty acid metabolism, <br /> kinetoplastids undergo RNA editing produce mature func-                            (Hashimi et al., 2010; Schnaufer et al., 2005). Encouragingly, sev- <br /> tional mRNAs translated multiple essential compo-                           eral proteins involved editing process essential <br /> nents mitochondrial oxidative phosphorylation                               growth <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span>survival</span> BF (Baldassarre et al., 2003; <br /> (Hannaert et al., 2003; Madison-Antenucci et al., 2002). The insect                       Carnes et al., 2005; Deng et al., 2005; Drozdz et al., 2002; Guo <br />  <br />  <br />  <br />  <br /> Fig. 1. Schematic presentation RNA editing reactions. RNA editing entails maturation mitochondrial mRNAs insertion (left panel) deletion (right panel) of <br /> uridylates (Us) speci&#239;&#172;?ed small guide RNAs (gRNAs). The speci&#239;&#172;?c proteins involved catalytic reaction highlighted. <br />  38                                    R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br /> Table 1 <br /> Biological importance biochemical functions editosome proteins &#226;&#8364;&#8220; alternative nomenclatures mentioned (e.g. TbMP63, T. brucei mitochondrial protein 63 kDa). <br />  <br />      Protein              Proposed function          Essentiality   Technique       Effects RNA editing activities editosome       References <br />                                                                     used        complex <br />                                                                     inhibition <br />      KREPA1/TbMP81        RNA/protein                BF PF      RNAi-             - Inhibition vivo RNA editing                     Drozdz et al. (2002) <br />                           interaction                               mediated          - Loss endoribonuclease, TUTase RNA              O&#226;&#8364;&#8482;Hearn et al. (2003) <br />                                                                     repression          ligase activities associated insertion <br />                                                                                         editing <br />      KREPA2/TbMP63        RNA/protein                PF             RNAi-             - Great reduction endonuclease activity          Huang et al. (2002) <br />                           interaction                               mediated            U deletion U insertion <br />                                                                     repression        - Loss KREL1 <br />                                                                                       - Disruption proper editosome assembly <br />      KREPA3/TbMP42        RNA/protein                BF PF      Regulatable       - Complete loss editosome BF                      Brecht et al. (2005), Law et al. <br />                           interaction                               <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-162' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-176' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-213' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-216' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-228' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-236' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span>knockout</span>       - Reduced RNA editing activity PF                    (2008), Guo et al. (2008), Guo <br />                                                                     BF                - Inhibition endoribonucleolytic cleavage         et al. (2010) <br />                                                                     RNAi-               U deletion U insertion, steps <br />                                                                     mediated            affected <br />                                                                     repression <br />                                                                     PF <br />      KREPA4/TbMP24        RNA/protein                PF             RNAi-             - Loss editosome proteins                            Kala Salavati (2010), Salavati <br />                           interaction                               mediated          - Reduction U deletion U insertion          et al. (2006) <br />                                                                     repression        - Reduction editosome stability and/or inter- <br />                                                                                         ruption editosome assembly <br />      KREPA5/TbMP19        RNA/protein                N.D.           N.D.                                                                      Carnes et al. (2011), Panigrahi <br />                           interaction                                                                                                         et al. (2006) <br />      KREPA6/TbMP18        RNA/protein                PF             RNAi-             - Loss U deletion U insertion               Tarun et al. (2008) <br />                           interaction                               mediated          - Loss structural integrity editosome <br />                                                                     repression <br />      KREN1/TbMP90         U deletion-speci&#239;&#172;?c         BF PF      RNAi-             - Inhibition vivo editing                         Kang et al. (2006), Trotter et al. <br />                           endonuclease                              mediated          - Inhibition vitro endoribonucleolytic cleav-     (2005) <br />                                                                     repression          age deletion substrates; cleavage insertion <br />                                                                     PF               substrates catalytic activities edit- <br />                                                                     Regulatable         ing affected <br />                                                                     knockout in <br />                                                                     BF <br />      KREN3/TbMP67         Endonuclease speci&#239;&#172;?c       BF             Regulatable       - Elimination COII RNA editing vivo               Carnes et al. (2008) <br />                           Cytochrome                            knockout          - Inhibition endonucleolytic cleavage COII <br />                           oxidase II pre-edited                                         RNA substrate vitro <br />                           mRNA                                                        - Editosomes vitro catalytic activities <br />                                                                                         (based A6 derived RNA substrates) retained <br />      KREN2/TbMP61         Insertion-speci&#239;&#172;?c          BF PF      RNAi-             - Inhibition vivo editing PF BF            Carnes et al. (2005) <br />                           endonuclease activity                     mediated          - Inhibition vitro cleavage insertion edit- <br />                                                                     repression          ing substrates; cleavage deletion substrates <br />                                                                     PF               catalytic activities editing not <br />                                                                     Regulatable         affected <br />                                                                     knockout in <br />                                                                     BF <br />      KREPB4/TbMP46        RNA/protein                PF             RNAi-             - Altered editosome integrity abundance             Babbarwal et al. (2007) <br />                           interaction                               mediated          - Reduced vivo RNA editing <br />                                                                     repression        - Reduced insertion deletion endonuclease <br />                                                                                         activities <br />      KREPB5/TbMP44        RNA/protein                BF             Regulatable       - Loss editing vivo                               Baldassarre et al. (2003) <br />                           interaction                               knockout          - Loss editing-associated catalytic activities <br />                                                                                         vitro <br />                                                                                       - Perturbation editosome structure <br />      KREPB6/TbMP49        RNA/protein                N.D.           N.D.                                                                      Panigrahi et al. (2006), Carnes <br />                           interaction                                                                                                         et al. (2011) <br />      KREPB7/TbMP47        RNA/protein                N.D.           N.D.                                                                      Panigrahi et al. (2006), Carnes <br />                           interaction                                                                                                         et al. (2011) <br />      KREPB8/TbMP41        RNA/protein                N.D.           N.D.                                                                      Panigrahi et al. (2006), Carnes <br />                           interaction                                                                                                         et al. (2011) <br />      KREL1/TbMP52         Deletion-speci&#239;&#172;?c           BF             Regulatable       - Complete inhibition RNA editing                    Schnaufer et al. (2001), Cruz- <br />                           Ligase                                    knockout                                                                  Reyes et al. (2002) <br />      KREL2/TbMP48         Insertion-speci&#239;&#172;?c          Not            RNAi-             - No effect RNA editing                              Drozdz et al. (2002), Gao and <br />                           Ligase                     essential   mediated                                                                  Simpson (2003), Cruz-Reyes <br />                                                      BF PF      repression                                                                et al. (2002) <br />      KREX1/TbMP100        30 &#226;&#8364;&#8220;50 exonuclease         PF             RNAi-             - Disruption editosome                               Kang et al. (2005), Rogers et al. <br />                           responsible U-                        mediated          - Reduction KREN1 editosomes                      (2007), Ernst et al. (2009) <br />                           deletion                                  repression        - Preferential Inhibition of <br />                                                                                       - In vitro pre-cleaved U-deletion editing <br />      KREX2/TbMP99         30 &#226;&#8364;&#8220;50 exonuclease         PF (Minor      RNAi-             - Little effect editosome stability                  Rogers et al. (2007), Ernst et al. <br />                           activity                   effect      mediated          - Reductions KREPA2 KREL1 editosomes          (2009) <br />                                                      cell           repression        - Modest reductions insertion dele- <br />                                                      growth)                            tion endonuclease activities <br />                                                                                       - Signi&#239;&#172;?cant reduction U removal vitro <br />                                      R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46                                      39 <br />  <br />  <br /> Table 1 (continued) <br />  <br />   Protein               Proposed function          Essentiality   Technique       Effects RNA editing activities editosome       References <br />                                                                   used        complex <br />                                                                   inhibition <br />   KRET1                 Guide RNA-speci&#239;&#172;?c          PF             RNAi-             - Reduction RNA editing                              Aphasizhev et al. (2002), Ernst <br />                         TUTase                                    mediated          - Accumulation guide RNA shorter U tails        et al. (2003) <br />                                                                   repression <br />   KRET2/TbMP57          U insertion-speci&#239;&#172;?c        PF             RNAi-             - Complete inhibition U-insertion vitro           Aphasizhev et al. (2003c), Ernst <br />                         TUTase                                    mediated          - No effect <span id='am-2' about='xsp:length' typeof='owl:Thing'>length</span> guide RNA oligo(U)         et al. (2003) <br />                                                                   repression          tails <br />   KREH1/mHel61p         Helicase activity          PF             Knockout          - Reduced amounts edited mRNAs                       Missel et al. (1997), Li et al. <br />                                                                                                                                             (2011) <br />  <br /> N.D.: determined. <br />  <br />  <br />  <br />  <br /> et al., 2008; Law et al., 2008; O&#226;&#8364;&#8482;Hearn et al., 2003; Schnaufer et al.,                  expression and/or stability gRNAs edited pre-edi- <br /> 2001; Trotter et al., 2005). Therefore, editing essential process                  ted mRNAs (Acestor et al., 2009; Ammerman et al., 2008, 2011, <br /> in life stages. This observation suggests important                             2010; Hashimi et al., 2009, 2008; Hernandez et al., 2010; Panigrahi <br /> possibility RNA editing process provide similar                         et al., 2008; Weng et al., 2008). <br /> ef&#239;&#172;?cient chemotherapeutic targets medically <br /> important trypanosomatid parasites. Furthermore, type                            3. The editosome composition <br /> RNA editing unique parasites; hence, targeting this <br /> process effects human host.                              The functional editosome proteins identi&#239;&#172;?ed several <br />     Here review recent advances development new                        methods including mass spectrometric analysis editosomes that <br /> methods discover potential inhibitors RNA editing T. brucei.                    puri&#239;&#172;?ed serial ion exchange gel permeation chroma- <br /> We highlight recently reported inhibitors RNA                           tography, immunoaf&#239;&#172;?nity chromatography speci&#239;&#172;?c editosome <br /> editing contribute functional studies essen-                     proteins, tandem af&#239;&#172;?nity puri&#239;&#172;?cation (TAP) based tagged <br /> tial RNA processing mechanism exciting possibility                         RNA editing proteins (Aphasizhev et al., 2003a; Panigrahi et al., <br /> future drug development related trypanosomatid                         2006, 2001a,b, 2003; Rusche et al., 1997). Several nomenclatures <br /> pathogens.                                                                               proposed literature editosome pro- <br />                                                                                          teins (Panigrahi et al., 2001a; Peris et al., 1997; Rusche et al., <br /> 2. RNA editing process                                                                   1997; Simpson et al., 2010; Stuart et al., 2005). Here use <br />                                                                                          nomenclature proposed Stuart et al., Kinetoplastid <br />     In vitro studies using mitochondrial extract T. brucei (Seiw-                   RNA editing (KRE) pre&#239;&#172;?x followed abbreviation func- <br /> ert et al., 1996) indicate RNA editing mediated series                   tion experimentally known (Stuart et al., 2005). The letter K will <br /> coordinated catalytic steps multi-protein complexes known                          replaced species&#226;&#8364;&#8482; abbreviation speci&#239;&#172;?cally discussed <br /> editosomes, insert delete uridylates (Us) speci&#239;&#172;?ed                          article. Proteins catalyze exoUase (KREX1 and <br /> by guide RNAs (gRNAs) (Aphasizhev Aphasizheva, 2011; Blum                            KREX2) (Ernst et al., 2009; Kang et al., 2005; Rogers et al., 2007), <br /> et al., 1990; Osato et al., 2009; Simpson et al., 2003, 2000; Sturm                      TUTase (KRET2) (Aphasizhev et al., 2003c; Ernst et al., 2003), ligase <br /> and Simpson, 1990). The initial event editing reaction                         (KREL1 KREL2) (McManus et al., 2001; Rusche et al., 2001; <br /> hybridization 50 end gRNA precursor mRNA                            Schnaufer et al., 2001), endonuclease (KREN1, KREN2, KREN3) <br /> (pre-edited mRNA) just downstream &#239;&#172;?rst editing site,                           (Carnes et al., 2005, 2008; Trotter et al., 2005), helicase <br /> form anchor duplex (Blum et al., 1990). The catalytic cascade                         (KREH1) (Li et al., 2009; Missel et al., 1997) activities editing <br /> of RNA editing occurs endonucleolytic cleavage precursor                       identi&#239;&#172;?ed functionally characterized (Fig. 1). The <br /> mRNA editing site, U addition 30 -terminal uridylyl trans-                     number proteins fully functional editosome known; <br /> ferase (TUTase) activity removal 30 exouridylylase activity                        however, recent studies identi&#239;&#172;?ed 20 pro- <br /> (exoUase) 30 end 50 cleavage fragment, sub-                       teins (Table 1) highly dynamic components complexes, <br /> sequent ligation RNA fragments RNA ligase activity, re-                        common set core proteins, associated a <br /> viewed (Hajduk Ochsenreiter, 2010; Stuart et al., 1997)                           different endonuclease (KREN1&#226;&#8364;&#8220;3) (Carnes et al., 2011, 2008; <br /> (Fig. 1). In addition, editosome contains RNA editing-associated                     Panigrahi et al., 2006; Trotter et al., 2005). These complexes sedi- <br /> RNA helicase activity, affect gRNA/mRNA interactions                           ment   20 Svedberg (20S) glycerol gradients are <br /> and/or displace gRNA use (Missel et al., 1997).                                known &#226;&#8364;&#732;20S editosome&#226;&#8364;&#8482; (Carnes et al., 2008; Panigrahi et al., <br />     RNA editing appears involve dynamic interactions multiple                      2006). These editosomes represent &#226;&#8364;&#732;&#226;&#8364;&#732;catalytic core complex&#226;&#8364;&#8482;&#226;&#8364;&#8482; <br /> proteins complexes directly core edito-                     additional proteins contribute RNA editing vivo. Mul- <br /> some, indirectly regulate ef&#239;&#172;?ciency editing edito-                        ti-subunit complexes comprised separate insertion deletion <br /> some stability. For example, MRP complex, consists                          activities sedimenting  5&#226;&#8364;&#8220;10S proposed <br /> MRP1 MRP2 proteins, matchmaking type RNA anneal-                            contribute assembly entire system <br /> ing activity (Muller Goringer, 2002; Schumacher et al., 2006;                        (Schnaufer et al., 2003). Whether editosomes contain catalytic or <br /> Zikova et al., 2008). RBP16 plays role gRNA/pre-mRNA                           structural RNA unknown. <br /> interaction shown overlapping function                               The editosome proteins related pairs sets sequence <br /> with MRP1 MRP2 proteins (Ammerman et al., 2008; Fisk                                 motif similarities re&#239;&#172;&#8218;ect functions predicted <br /> et al., 2009). The mitochondrial RNA binding complex 1 (MRB1)                            catalytic and/or RNA interaction motifs (Worthey et al., 2003). For <br /> or guide RNA binding complex (GRBC), share number                            instance, editosome RNA ligases similar (41% identity) <br /> of common protein components likely represent par-                          lines evidence suggested KREL1 involved <br /> ticle, recently described play role diverse aspects                    U-deletion editing KREL2 involved U-insertion editing, <br /> of mitochondrial RNA metabolism gRNA utilization                             leading proposed structural functional division the <br />  40                              R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br /> editosome model insertion deletion sub-complexes                            date. In section, focus recent developments vir- <br /> (Schnaufer et al., 2003). KREPA1&#226;&#8364;&#8220;6 additional editosome                      tual chemical screening libraries identi&#239;&#172;?cation of <br /> proteins share C-terminal motif associated oligo-                    chemical compounds target editosome. <br /> nucleotide-binding (OB) fold varying degrees relatedness <br /> (Worthey et al., 2003). The largest &#239;&#172;?ve proteins                 5.1. Virtual screening methods <br /> have C2H2 zinc &#239;&#172;?nger motifs, suggesting possible RNA/protein- <br /> binding functions. The speci&#239;&#172;?c functions proteins                        Virtual screening emerged important tool discov- <br /> not known; however, recent data propose extensive protein&#226;&#8364;&#8220;                       ery drug-like compounds speci&#239;&#172;?c target (Kuntz, <br /> protein interactions mediated OB-fold proteins, coordi-                  1992; Maryanoff, 2004; Shoichet, 2004; Shoichet et al., 2002; Var- <br /> nating editosome function (Schnaufer et al., 2010).                              ney et al., 1992; von Itzstein et al., 1993). Currently, various proto- <br />                                                                                      cols available virtual screening chemical compound <br />                                                                                      databases. Overall, virtual screening contains following two <br /> 4. Editosome drug target <br />                                                                                      steps: (i) rapid docking algorithms used order identify <br />                                                                                      likely position orientation available candidate <br />     Gene inactivation studies RNA editing ligase 1 T. brucei <br />                                                                                      compounds active site protein interest; (ii) the <br /> (TbREL1) showed &#239;&#172;?rst time RNA editing essential <br />                                                                                      compound activity ranked analyzing steric electro- <br /> in BF (Schnaufer et al., 2001). Subsequent RNAi mediated repres- <br />                                                                                      static properties predicted protein&#226;&#8364;&#8220;ligand complex (Reddy <br /> sion <span id='am-238' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-239' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-240' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-241' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-243' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-247' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-252' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-253' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-255' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-260' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-261' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-266' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-268' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-270' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-276' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-281' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-283' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-286' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-290' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-292' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-303' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-310' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-312' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-313' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-315' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span>gene knockout</span> studies functionally character- <br />                                                                                      et al., 2007). This approach used recently (Amaro et al., <br /> ized editosome proteins shown RNA editing essential <br />                                                                                      2008; Durrant et al., 2010; Moshiri et al., 2011) order &#239;&#172;?nd po- <br /> in life cycle stages parasite (Table 1). It men- <br />                                                                                      tential drug-like compounds TbREL1, essential <br /> tioned &#226;&#8364;&#732;&#226;&#8364;&#732;dyskinetoplastic&#226;&#8364;&#8482;&#226;&#8364;&#8482; trypanosomes have <br />                                                                                      enzymes editosome N-terminal high-resolution crys- <br /> partially lost kinetoplast (Brun et al., 1998), the <br />                                                                                      tal structure available (Deng et al., 2004). Moreover, no <br /> RNA editing process suggested dispensable. For <br />                                                                                      close human homologs; hence, TbREL1 used ideal che- <br /> example, shown dyskinetoplastic Trypano- <br />                                                                                      motherapeutic target designing selective inhibitors block <br /> soma evansi, editosome proteins expressed even <br />                                                                                      essential RNA ligase function. <br /> imported mitochondrion, function essential <br />                                                                                           The ligation mechanism TbREL1 similar DNA li- <br /> (Paris et al., 2011). This loss essentiality hypothesized <br />                                                                                      gases, structures different. The ligation reaction <br /> <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> result compensatory <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-85' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-102' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-132' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span>mutation</span> nuclear-encoded <br />                                                                                      follows steps (Fig. 2): (i) adenylylation step, the <br /> subunit mitochondrial ATP synthase (Lai et al., 2008; <br />                                                                                      conserved catalytic lysine attacks a-phosphate ATP releases <br /> Schnaufer et al., 2005, 2002). Therefore, drugs targeting RNA edit- <br />                                                                                      pyrophosphate. At step, enzyme-AMP intermediate is <br /> ing machinery likely work dyskinetoplastic para- <br />                                                                                      formed phosphoamide linkage; (ii) The deadenylyla- <br /> sites livestock, T. evansi T. equipedrum. However, <br />                                                                                      tion step, TbREL1-AMP recognize double-stranded <br /> as mentioned before, RNA editing essential known trypan- <br />                                                                                      nicked mRNA/gRNA transfer bound AMP 50 -phos- <br /> osomatid parasites human, including closely related T. bru- <br />                                                                                      phate RNA molecule, forming adenylylated RNA a <br /> cei, T. cruzi Leishmania spp. Therefore, RNA editing viable <br />                                                                                      50 ,50 -phosphoanhydride bond; (iii) The ligation step, the <br /> drug target, indicating need development methods for <br />                                                                                      free 30 -hydroxyl 50 fragment attacks phosphoanhydride <br /> discovery new chemical compounds inhibit pro- <br />                                                                                      bond adenylylated 30 RNA fragment nick site, leading <br /> cess. In sections, discuss methods the <br />                                                                                      formation phosphodiester bond release AMP. <br /> compounds discovered. <br />                                                                                           Recent studies performed virtual screening various <br />                                                                                      compounds high-resolution structure TbREL1 order <br /> 5. High-throughput screening (HTS) methods: virtual                              identify compounds inhibit adenylylation step by <br /> chemical                                                                             competing ATP active site. In &#239;&#172;?rst study, Amaro <br />                                                                                      et al. (2008) initially used structure-based virtual screening li- <br />     In review, chosen focus attention dis-                brary compounds National Cancer Institute (NCI) iden- <br /> covery development innovative therapeutic agents tar-                    tify compounds highest binding af&#239;&#172;?nity. This <br /> get RNA editing. Target-driven approaches identify chemicals                     resulted set drug-like candidate compounds, named V1 to <br /> that speci&#239;&#172;?cally affect certain biological process minimal                    V8. Since compounds predicted bind ATP- <br /> off-targets effects (Ilag et al., 2002; Westwell Stevens, 2004).                 binding pocket TbREL1, effect TbREL1 adenylylation <br /> Identi&#239;&#172;?cation validated druggable biological targets                     tested experimentally; V1 V4 showed highest inhibi- <br /> essential roles cell &#239;&#172;?rst step target-driven                   tion adenylylation step candidates. Amaro et al. <br /> drug discovery. The target speci&#239;&#172;?c protein essen-                   used ligand-based virtual screening, searched <br /> tial function, TbREL1. Alternatively, essential protein                   compounds highest similarity V1. They came up <br /> complex biological process considered target,                  compounds predicted high <br /> as editosome. In case, drug discovery process                  af&#239;&#172;?nity TbREL1 ATP-binding pocket, named S1 S6, among <br /> unbiased speci&#239;&#172;?c protein, chances identifying                   S5 shown experimentally highest inhibitory <br /> an effective compound higher. The second step consists                      effect TbREL1 (Table 2). These drugs reported an <br /> &#226;&#8364;&#732;&#226;&#8364;&#732;molecule hunt&#226;&#8364;&#8482;&#226;&#8364;&#8482; involves HTS libraries small-molecule                  vitro effect adenylylation step, did not <br /> compounds order identify hit. Modern approaches                      phenotypic effect cultured T. brucei cells, most <br /> combinatorial chemistry, structural biology computational                        probably cells permeable com- <br /> analysis leveraged increase chances success                 pounds. Furthermore, inhibitory effect TbREL1 clo- <br /> step minimize required time. The step known                       sely related T4 RNA ligase 2 comparison human DNA ligase III <br /> hit-to-lead development, aim identifying lead com-                     suggests selectivity RNA ligases. Later, study, Dur- <br /> pound drug-like properties active cellular con-                  rant et al. performed virtual screening TbREL1 using li- <br /> text. Lastly, lead development step test optimize                   brary compounds similar core naphthalene <br /> pharmacokinetic pharmacodynamic properties lead                           scaffold previously TbREL1 inhibitors, resulting no- <br /> compounds vivo, identi&#239;&#172;?cation clinical candi-                    vel compounds named V1 V4 (Durrant et al., 2010). Among these <br />                                 R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46                   41 <br />  <br />  <br />  <br />  <br />                               Fig. 2. The schematic presentation three-step ligation mechanism RNA editing ligase 1. <br />  <br />  <br />  <br /> compounds, V2 V4 shown inhibit adenylylation                        sensitivity, speci&#239;&#172;?city reproducibility assay [collectively <br /> step ef&#239;&#172;?ciently, V4 able kill parasite well.                 measured important statistical parameter called Z-factor <br /> Simultaneously, Moshiri et al., performed structure-based virtual                   (Zhang et al., 1999)], manageability compound library, and <br /> screening TbREL1 (Moshiri et al., 2011), resulting 12 po-                suitability reagents large-scale screening most <br /> tential inhibitors TbREL1 adenylylation, shown                  important factors order develop successful HTS assay. Two <br /> experimentally inhibit full-round RNA editing reaction. This                     types HTS assays developed; homogeneous assays and <br /> compound, named C35, turned the com-                          heterogeneous assay. Homogeneous assays simpler include <br /> pound V2 Durrant et al. Moshiri et al. performed                     straightforward steps addition reagents, incubation, and <br /> the docking single protein conformation based avail-                    reading, heterogeneous assays cumbersome due <br /> able crystal structure TbREL1, Durrant et al. used &#226;&#8364;&#732;&#226;&#8364;&#732;relaxed                 requirement extra steps washing steps, <br /> complex scheme&#226;&#8364;&#8482;&#226;&#8364;&#8482;, compounds docked                          &#239;&#172;?ltration, centrifugation. Hence, ideal HTS assay be <br /> ensemble 30 protein conformations obtained molecular                        homogenous, inexpensive, minimal requirement complex <br /> dynamic simulations.                                                                instrumentation. <br />    According studies, predicted binding mode C35                        Recently, HTS assays designed developed for <br /> (V2) (Durrant et al., 2010; Moshiri et al., 2011) follow: theo-               screening different chemical libraries editosome <br /> retically, interaction compound TbREL1 mimics                      (Fig. 3) (Liang Connell, 2009; Moshiri Salavati, 2010). Liang <br /> certain aspects ATP binding. Similar adenine moiety                    et al. developed heterogeneous RNA aptamer-based assay in <br /> ATP, naphthalene rings C35 forms p&#226;&#8364;&#8220;p stacking                       RNA editing reaction monitored using electroche- <br /> interaction Phe209. Also, similar triphosphate tail                  miluminescent signal. In study, successful U-insertion <br /> ATP, sulfonate group forms ion pair guanidine group                   RNA editing, RNA aptamer undergoes conformational change <br /> of Arg111. Aminonaphthyl group forms water-mediated interac-                      activates streptavidin-binding region, resulting mea- <br /> tion Arg288 similar N1 atom adenine moiety                    surable electrochemiluminescent signal. In study by <br /> ATP. While inhibitor predicted bind deep binding                  Moshiri et al., simple &#226;&#8364;&#732;mix measure&#226;&#8364;&#8482; homogeneous HTS assay <br /> pocket active site, study Durrant et al. revealed no-               based &#239;&#172;&#8218;uorescence resonance energy transfer (FRET) been <br /> vel predicted drug binding site periphery TbREL1 ac-                  developed. This assay uses hammerhead ribozyme RNA edit- <br /> tive site, potentially harnessed design speci&#239;&#172;?c                     ing substrate. Upon successful U-deletion RNA editing, inactive <br /> inhibitors, given low similarity region counter-               ribozyme active able cleave 16-nucleotide <br /> part human DNA ligase.                                                           FRET substrate carries &#239;&#172;&#8218;uorescent reporter (FAM) 50 <br />    Drug discovery relies experimental validation identi&#239;&#172;?ca-                  end quencher (TAMRA) 30 end, resulting detect- <br /> tion compounds real inhibitory effect target. In                 able signal. While methods monitor activity the <br /> next section, discuss methods validation computa-                    editosome context U-deletion U-insertion <br /> tionally identi&#239;&#172;?ed chemicals, direct discovery                    RNA editing, novel methods developed speci&#239;&#172;?- <br /> inhibitory compounds chemical compound libraries.                              cally monitor ligase activity TbREL1 (Hall Schnaufer, <br />                                                                                     Kinetoplastid Molecular Cell Biology meeting, 2011). The availabil- <br /> 5.2. Chemical HTS methods                                                           ity different methods provides opportunity &#239;&#172;?nd <br />                                                                                     inhibitors wide range RNA editing-related activities. <br />    In order design successful high-throughput screening assay,                 In section, recently inhibitors <br /> several factors taken consideration. For example,                    RNA editing based assays virtual screening. <br />  42                                    R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br /> Table 2 <br /> The potent inhibitors RNA editing possible mode action. <br />  <br />      ID/source               Structure                                         IC50 (lM) based   IC50 (lM) based     Potential mode           References <br />                                                                                adenylylation        full-round RNA         inhibition <br />                                                                                activity             editing activity <br />      V4, Sigma Mordant                                                         1.59 &#194;&#177; 1.10          N.D.                   Adenylylation               Durrant et al. (2010) <br />         Black 25 <br />  <br />  <br />  <br />  <br />      C35/V2, NSC162535                                                         1.53 &#194;&#177; 1.17          N.D.                   Deadenylylation/            Durrant et al. (2010), <br />                                                                                                                            adenylylation/RNA&#226;&#8364;&#8220;          Moshiri et al. (2011) <br />                                                                                                                            protein interaction <br />  <br />  <br />  <br />  <br />      V1, NSC45609                                                              2.16 &#194;&#177; 1.20          N.D.                   Adenylylation               Durrant et al. (2010) <br />  <br />  <br />  <br />  <br />      V3, NSC1698                                                               8.36 &#194;&#177; 1.71          N.D.                   Adenylylation               Durrant et al. (2010) <br />  <br />  <br />  <br />  <br />      S5, NSC16209                                                              1.01 &#194;&#177; 0.16          2.1 &#194;&#177; 0.4              Deadenylylation/            Amaro et al. (2008), <br />                                                                                                                            adenylylation/RNA&#226;&#8364;&#8220;          Moshiri et al. (2011), <br />                                                                                                                            protein interaction         Moshiri Salavati <br />                                                                                                                                                        (2010) <br />  <br />  <br />  <br />  <br />      S1, NSC100234                                                             1.95 &#194;&#177; 0.61          N.D.                   Adenylylation               Amaro et al. (2008) <br />  <br />  <br />  <br />  <br />      NF023                                                                     N.D.                 2.9 &#194;&#177; 0.7              RNA editing    Liang Connell <br />                                                                                                                            endonuclease cleavage   (2010) <br />                                                                                                                            step/global effect on <br />                                                                                                                            editing complex <br />  <br />  <br />  <br />  <br />      Mitoxantrone                                                              N.D.                 2.6 &#194;&#177; 0.5              RNA editing    Liang Connell <br />                                                                                                                            endonuclease cleavage   (2010) <br />                                                                                                                            step/global effect on <br />                                                                                                                            editing complex <br />  <br />  <br />  <br />      D-Sphingosine                                                             N.D.                 2.0 &#194;&#177; 0.1              RNA editing       Liang Connell <br />                                                                                                                            endonuclease cleavage       (2010) <br />                                                                                                                            step/global effect on <br />                                                                                                                            editing complex <br />                                        R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46                                43 <br />  <br />  <br /> Table 2 (continued) <br />  <br />   ID/source                  Structure                                       IC50 (lM) based     IC50 (lM) based     Potential mode           References <br />                                                                              adenylylation          full-round RNA         inhibition <br />                                                                              activity               editing activity <br />   GW5074                                                                     N.D.                   2.9 &#194;&#177; 0.4              RNA editing    Liang Connell <br />                                                                                                                            endonuclease cleavage   (2010) <br />                                                                                                                            step <br />  <br />  <br />  <br />  <br />   Protoporphyrin IX                                                          N.D.                   0.9 &#194;&#177; 0.1              RNA editing    Liang Connell <br />                                                                                                                            endonuclease cleavage   (2010) <br />                                                                                                                            step <br />  <br />  <br />  <br />  <br /> N.D.: determined. <br />  <br />  <br />  <br />  <br /> Fig. 3. RNA editing assays developed high-throughput screening &#226;&#8364;&#8220; Left panel illustrates RNA aptamer-based assay. In assay, aptamer labeled <br /> with ruthenium (red ball) used, successful addition Us changes conformation and, activated, binding streptavidin coats <br /> the microtiter plate. Upon electrical stimulation, ruthenium complex generates measurable ECL signal. Right panel illustrates FRET-based assay, 16nt- <br /> long reporter RNA labeled &#239;&#172;&#8218;uorescent reporter (FAM, red ball) &#239;&#172;&#8218;uorescent quencher (TAMRA, blue ball). In assay, successful deletion Us <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br /> the catalytic core HHR, inactive HHR active cleaves reporter RNA generates detectable &#239;&#172;&#8218;uorescent signal. (For interpretation reference to <br /> colors &#239;&#172;?gure legend, reader referred web version article.) <br />  <br />  <br />  <br /> 6. Editosome inhibitors                                                                    et al. used editosome initial target drug discov- <br />                                                                                            ery, Amaro group Salavati group used essen- <br />     Liang et al. used aptamer-based assay screen library                     tial TbREL1 speci&#239;&#172;?c target screen chemical <br /> pharmacologically active compounds (LOPAC) RNA editing                             compounds inhibitors RNA editing. The Amaro group identi- <br /> machinery, 28 hits strong inhibitory effect RNA                          &#239;&#172;?ed naphthalene-based compounds virtual screen- <br /> editing (Liang Connell, 2010). By performing secondary assays,                         ing, reported inhibitory effect compounds the <br /> two compounds perturb endonuclease activ-                             adenylylation step ligation vitro using recombinant TbREL1 <br /> ity initial steps RNA editing process (Table 2). While Liang                     (Table 2). Two compounds, S5 C35 (V2), were <br />  44                              R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br /> later tested Salavati group editosome, showed                    compounds identi&#239;&#172;?ed spliceosome allowed dee- <br /> strong inhibition U-deletion RNA editing (Moshiri et al., 2011).                  understanding assembly functional spliceosome <br /> Secondary assays con&#239;&#172;?rmed compound inhibit                       blocking various stages assembly possessing anti- <br /> adenylylation TbREL1 low editosome concentrations,                        tumor activities (Albert et al., 2007; Kaida et al., 2007; Kotake et al., <br /> whereas higher editosome concentration, required                     2007; O&#226;&#8364;&#8482;Brien et al., 2008). We anticipate chemical com- <br /> obtaining full-round RNA editing, deadenylylation TbREL1                      pounds generated high throughput screening against <br /> was inhibited, adenylylation. Moshiri et al. suggested                  editosome block affect steps in <br /> that compounds able inhibit adenylylation                   editing cycle. These steps include potentially various stages <br /> TbREL1, mechanism drug                       editosome assembly, leading initiation catalytic <br /> exerts effect functional biological context (Moshiri et al.,              steps, editing multiple sites use multiple gRNAs, and <br /> 2011). Based observation compounds inhibited                       termination step. Due multi-subunit nature editosome <br /> all editing steps required RNA&#226;&#8364;&#8220;editosome interaction, Moshiri                   involve assembly units, &#239;&#172;?nd chem- <br /> et al. suggested C35 S5 inhibit interaction edi-                 ical genetics approach advantageous compared RNAi or <br /> tosome substrate RNA, supported claim di-                      gene replacement strategies, interfering editosome func- <br /> rectly examining effect compounds RNA&#226;&#8364;&#8220;                               tion assembly direct editosome binding. The characteristics <br /> editosome interaction. Consistent observations, C35                       alterations indicate likely functions speci&#239;&#172;?c compo- <br /> addition alter sedimentation pro&#239;&#172;?le 20S edi-                   nents editosome proteins order assembly. Thus, <br /> tosomes likely results direct perturbation                        development characterization editosome inhibitors not <br /> RNA&#226;&#8364;&#8220;protein interactions editosome assembly and/or                           provide opportunities possible therapeutics, tools <br /> integrity. These observations highlight potential use                    studying details editosome assembly function. <br /> compounds importance better understanding of <br /> TbREL1-inhibitor interaction editosome assembly. Taken to- <br /> gether, naphthalene-based compounds appear &#239;&#172;?nd addi-                        References <br /> tional targets anticipated ATP-binding pocket of <br /> TbREL1 context partially puri&#239;&#172;?ed functional editosomes.                    Acestor, N., Panigrahi, A.K., Carnes, J., Zikova, A., Stuart, K.D., 2009. The MRB1 <br /> These studies raise essential questions respect naph-                      complex functions kinetoplastid RNA processing. RNA 15, 277&#226;&#8364;&#8220;286. <br />                                                                                      Albert, B.J., Sivaramakrishnan, A., Naka, T., Czaicki, N.L., Koide, K., 2007. Total <br /> thalene-based inhibitors-TbREL1 interaction; inhibitors                           syntheses, fragmentation studies, antitumor/antiproliferative activities of <br /> bind similar distinct targets? Do interactions inhibitors af-                  FR901464 low picomolar analogue. J. Am. Chem. Soc. 129, 2648&#226;&#8364;&#8220;2659. <br /> fect TbREL1 sub-complex assembly and/or stability,                        Amaro, R.E., Schnaufer, A., Interthal, H., Hol, W., Stuart, K.D., McCammon, J.A., 2008. <br />                                                                                          Discovery drug-like inhibitors essential RNA-editing ligase in <br /> block recruitment editing substrates editosome?                            Trypanosoma brucei. Proc. Natl. Acad. Sci. USA 105, 17278&#226;&#8364;&#8220;17283. <br /> Studying mechanistic details inhibition TbREL1 activity                    Ammerman, M.L., Fisk, J.C., Read, L.K., 2008. GRNA/pre-mRNA annealing RNA <br /> by compounds provide valuable insights                            chaperone activities RBP16. RNA 14, 1069&#226;&#8364;&#8220;1080. <br />                                                                                      Ammerman, M.L., Hashimi, H., Novotna, L., Cicova, Z., McEvoy, S.M., Lukes, J., Read, <br /> the editosome assembly, instrumental determining                          L.K., 2011. MRB3010 core component MRB1 complex facilitates <br /> the mode action designing effective inhibitors                        early step kinetoplastid RNA editing process. RNA 17, 865&#226;&#8364;&#8220;877. <br /> editosome.                                                                           Ammerman, M.L., Presnyak, V., Fisk, J.C., Foda, B.M., Read, L.K., 2010. TbRGG2 <br />                                                                                          facilitates kinetoplastid RNA editing initiation progression past intrinsic <br />                                                                                          pause sites. RNA 16, 2239&#226;&#8364;&#8220;2251. <br /> 7. Conclusion prospects                                                          Aphasizhev, R., Aphasizheva, I., 2011. Uridine insertion/deletion editing in <br />                                                                                          trypanosomes: playground RNA-guided information transfer. Wiley <br />                                                                                          Interdiscip. Rev. RNA 2, 669&#226;&#8364;&#8220;685. <br />     Although recent studies provided insight                        Aphasizhev, R., Aphasizheva, I., Nelson, R.E., Gao, G., Simpson, A.M., Kang, X., Falick, <br /> structure editosome (Golas et al., 2009; Li et al., 2009),                        A.M., Sbicego, S., Simpson, L., 2003a. Isolation U-insertion/deletion editing <br />                                                                                          complex Leishmania tarentolae mitochondria. EMBO J. 22, 913&#226;&#8364;&#8220;924. <br /> mechanism sequence editosome assembly largely un-                          Aphasizhev, R., Aphasizheva, I., Nelson, R.E., Simpson, L., 2003b. A 100-kDa complex <br /> known. Acting editosome subunit, gRNA&#226;&#8364;&#8220;protein complex                            RNA-binding proteins mitochondria Leishmania tarentolae <br /> may bring gRNA editosome; however, con-                        catalyzes RNA annealing interacts RNA editing components. <br />                                                                                          RNA 9, 62&#226;&#8364;&#8220;76. <br /> &#239;&#172;?rmed (McManus et al., 2000). In studies, been <br />                                                                                      Aphasizhev, R., Aphasizheva, I., Simpson, L., 2003c. A tale TUTases. Proc. Natl. <br /> shown treatment editosome complex nucleases results                         Acad. Sci. USA 100, 10617&#226;&#8364;&#8220;10622. <br /> in disassembly complex loss editing activities, suggesting                 Aphasizhev, R., Sbicego, S., Peris, M., Jang, S.H., Aphasizheva, I., Simpson, A.M., Rivlin, <br /> a role RNA maintain editosome complex integrity (Apha-                        A., Simpson, L., 2002. Trypanosome mitochondrial 30 terminal uridylyl <br />                                                                                          transferase (TUTase): key enzyme U-insertion/deletion RNA editing. <br /> sizhev et al., 2003b; Salavati et al., 2002). On hand,                  Cell 108, 637&#226;&#8364;&#8220;648. <br /> been reported mutants lack mitochondrial DNA and,                          Babbarwal, V.K., Fleck, M., Ernst, N.L., Schnaufer, A., Stuart, K., 2007. An essential <br /> hence, lack mitochondrial mRNA gRNA contain catalytically                            role KREPB4 RNA editing structural integrity editosome in <br />                                                                                          Trypanosoma brucei. RNA 13, 737&#226;&#8364;&#8220;744. <br /> active editosomes (Domingo et al., 2003). These data suggest mito-                   Baldassarre, H., Keefer, C., Wang, B., Lazaris, A., Karatzas, C.N., 2003. Nuclear transfer <br /> chondrial encoded RNA required assembly func-                          goats using vitro matured oocytes recovered laparoscopic ovum pick- <br /> tional editosomes. Therefore, known RNA editing                        up. Clon. Stem Cells 5, 279&#226;&#8364;&#8220;285. <br />                                                                                      Benne, R., Van den Burg, J., Brakenhoff, J.P., Sloof, P., Van Boom, J.H., Tromp, M.C., <br /> is catalyzed editosome formed association                        1986. Major transcript frameshifted coxII gene trypanosome <br /> multi-subunit complexes RNA binding, similar ribo-                           mitochondria contains nucleotides encoded DNA. Cell <br /> some, RNAs stepwise manner                        46, 819&#226;&#8364;&#8220;826. <br />                                                                                      Blum, B., Bakalara, N., Simpson, L., 1990. A model RNA editing kinetoplastid <br /> discrete intermediates, similar spliceosome (Hoskins et al.,                      mitochondria: &#226;&#8364;&#732;&#226;&#8364;&#732;guide&#226;&#8364;&#8482;&#226;&#8364;&#8482; RNA molecules transcribed maxicircle DNA provide <br /> 2011). Asides use chemotherapeutic agents, small                           edited information. Cell 60, 189&#226;&#8364;&#8220;198. <br /> compounds provided wealth information regarding                        Brecht, M., Niemann, M., Schluter, E., Muller, U.F., Stuart, K., Goringer, H.U., 2005. <br />                                                                                          TbMP42, protein component RNA editing complex African <br /> conformational dynamics ribosome. For instance, paromomycin, <br />                                                                                          trypanosomes, endo-exoribonuclease activity. Mol. Cell 17, 621&#226;&#8364;&#8220;630. <br /> puromycin, erythromycin, viomycin, quite useful                     Brun, R., Hecker, H., Lun, Z.R., 1998. Trypanosoma evansi T. equiperdum: <br /> helping understand ribosomal function assembly, recog-                        distribution, biology, treatment phylogenetic relationship (a review). Vet. <br /> nition tRNAs, translation trapping ribosome                          Parasitol. 79, 95&#226;&#8364;&#8220;107. <br />                                                                                      Buckner, F.S., Wilson, A.J., White, T.C., Van Voorhis, W.C., 1998. Induction of <br /> intermediate state (Douthwaite et al., 1985; Ermolenko et al.,                           resistance azole drugs Trypanosoma cruzi. Antimicrob. Agents Chemother. <br /> 2007; Moazed Noller, 1989; Yoshizawa et al., 1999). Similarly,                       42, 3245&#226;&#8364;&#8220;3250. <br />                                           R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46                                           45 <br />  <br />  <br /> Carnes, J., Soares, C.Z., Wickham, C., Stuart, K., 2011. Endonuclease associations       Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., <br />      distinct editosomes Trypanosoma brucei. J. Biol. Chem. 286, 19320&#226;&#8364;&#8220;                   Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., Tani, T., Horinouchi, S., <br />      19330.                                                                                        Yoshida, M., 2007. Spliceostatin A targets SF3b inhibits splicing and <br /> Carnes, J., Trotter, J.R., Ernst, N.L., Steinberg, A., Stuart, K., 2005. An essential RNase        nuclear retention pre-mRNA. Nat. Chem. Biol. 3, 576&#226;&#8364;&#8220;583. <br />      III insertion editing endonuclease Trypanosoma brucei. Proc. Natl. Acad. Sci.         Kala, S., Salavati, R., 2010. OB-fold domain KREPA4 mediates high-af&#239;&#172;?nity <br />      USA 102, 16614&#226;&#8364;&#8220;16619.                                                                         interaction guide RNA possesses annealing activity. RNA 16, 1951&#226;&#8364;&#8220; <br /> Carnes, J., Trotter, J.R., Peltan, A., Fleck, M., Stuart, K., 2008. RNA editing                 1967. <br />      Trypanosoma brucei requires different editosomes. Mol. Cell. Biol. 28,             Kang, X., Gao, G., Rogers, K., Falick, A.M., Zhou, S., Simpson, L., 2006. Reconstitution <br />      122&#226;&#8364;&#8220;130.                                                                                      full-round uridine-deletion RNA editing recombinant proteins. <br /> Croft, S.L., Barrett, M.P., Urbina, J.A., 2005. Chemotherapy trypanosomiases                Proc. Natl. Acad. Sci. USA 103, 13944&#226;&#8364;&#8220;13949. <br />      leishmaniasis. Trends Parasitol. 21, 508&#226;&#8364;&#8220;512.                                            Kang, X., Rogers, K., Gao, G., Falick, A.M., Zhou, S., Simpson, L., 2005. Reconstitution <br /> Cruz-Reyes, J., Zhelonkina, A.G., Huang, C.E., Sollner-Webb, B., 2002. Distinct                    uridine-deletion precleaved RNA editing recombinant enzymes. <br />      functions RNA ligases active Trypanosoma brucei RNA editing                         Proc. Natl. Acad. Sci. USA 102, 1017&#226;&#8364;&#8220;1022. <br />      complexes. Mol. Cell. Biol. 22, 4652&#226;&#8364;&#8220;4660.                                               Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., <br /> Delespaux, V., Koning, H.P., 2007. Drugs drug resistance African                         Ishihama, Y., Iwata, M., Mizui, Y., 2007. Splicing factor SF3b target the <br />      trypanosomiasis. Drug Resist. Updat. 10, 30&#226;&#8364;&#8220;50.                                               antitumor natural product pladienolide. Nat. Chem. Biol. 3, 570&#226;&#8364;&#8220;575. <br /> den Boer, M., Davidson, R.N., 2006. Treatment options visceral leishmaniasis.             Kuntz, I.D., 1992. Structure-based strategies drug design discovery. Science <br />      Expert Rev. Anti. Infect. Ther. 4, 187&#226;&#8364;&#8220;197.                                                   257, 1078&#226;&#8364;&#8220;1082. <br /> Deng, J., Ernst, N.L., Turley, S., Stuart, K.D., Hol, W.G., 2005. Structural basis UTP    Lai, D.H., Hashimi, H., Lun, Z.R., Ayala, F.J., Lukes, J., 2008. Adaptations of <br />      speci&#239;&#172;?city RNA editing TUTases Trypanosoma brucei. EMBO J. 24, 4007&#226;&#8364;&#8220;                  Trypanosoma brucei gradual loss kinetoplast DNA: Trypanosoma <br />      4017.                                                                                         equiperdum Trypanosoma evansi petite mutants T. brucei. Proc. Natl. <br /> Deng, J., Schnaufer, A., Salavati, R., Stuart, K.D., Hol, W.G., 2004. High resolution              Acad. Sci. USA 105, 1999&#226;&#8364;&#8220;2004. <br />      crystal structure key editosome enzyme Trypanosoma brucei: RNA                 Law, J.A., O&#226;&#8364;&#8482;Hearn, S.F., Sollner-Webb, B., 2008. Trypanosoma brucei RNA editing <br />      editing ligase 1. J. Mol. Biol. 343, 601&#226;&#8364;&#8220;613.                                                 protein TbMP42 (band VI) crucial endonucleolytic cleavages not <br /> Domingo, G.J., Palazzo, S.S., Wang, B., Pannicucci, B., Salavati, R., Stuart, K.D., 2003.          subsequent steps U-deletion U-insertion. RNA 14, 1187&#226;&#8364;&#8220;1200. <br />      Dyskinetoplastic Trypanosoma brucei contains functional editing complexes.               Li, F., Ge, P., Hui, W.H., Atanasov, I., Rogers, K., Guo, Q., Osato, D., Falick, A.M., Zhou, <br />      Eukaryot. Cell 2, 569&#226;&#8364;&#8220;577.                                                                    Z.H., Simpson, L., 2009. Structure core editing complex (L-complex) <br /> Douthwaite, S., Prince, J.B., Noller, H.F., 1985. Evidence functional interaction              involved uridine insertion/deletion RNA editing trypanosomatid <br />      domains II V 23S ribosomal RNA erythromycin-                           mitochondria. Proc. Natl. Acad. Sci. USA 106, 12306&#226;&#8364;&#8220;12310. <br />      resistant mutant. Proc. Natl. Acad. Sci. USA 82, 8330&#226;&#8364;&#8220;8334.                              Li, F., Herrera, J., Zhou, S., Maslov, D.A., Simpson, L., 2011. Trypanosome REH1 an <br /> Drozdz, M., Palazzo, S.S., Salavati, R., O&#226;&#8364;&#8482;Rear, J., Clayton, C., Stuart, K., 2002. TbMP81         RNA helicase involved 30 &#226;&#8364;&#8220;50 polarity multiple gRNA-guided uridine <br />      required RNA editing Trypanosoma brucei. EMBO J. 21, 1791&#226;&#8364;&#8220;1799.                     insertion/deletion RNA editing. Proc. Natl. Acad. Sci. USA 108, 3542&#226;&#8364;&#8220;3547. <br /> Durrant, J.D., Hall, L., Swift, R.V., Landon, M., Schnaufer, A., Amaro, R.E., 2010. Novel     Liang, S., Connell, G.J., 2009. An electrochemiluminescent aptamer switch high- <br />      naphthalene-based inhibitors Trypanosoma brucei RNA editing ligase 1. PLoS                 throughput assay RNA editing reaction. RNA 15, 1929&#226;&#8364;&#8220;1938. <br />      Negl. Trop. Dis. 4, e803.                                                                Liang, S., Connell, G.J., 2010. Identi&#239;&#172;?cation speci&#239;&#172;?c inhibitors a <br /> Ermolenko, D.N., Spiegel, P.C., Majumdar, Z.K., Hickerson, R.P., Clegg, R.M., Noller,              trypanosomatid RNA editing reaction. RNA 16, 2435&#226;&#8364;&#8220;2441. <br />      H.F., 2007. The antibiotic viomycin traps ribosome intermediate state          Madison-Antenucci, S., Grams, J., Hajduk, S.L., 2002. Editing machines: the <br />      translocation. Nat. Struct. Mol. Biol. 14, 493&#226;&#8364;&#8220;497.                                        complexities trypanosome RNA editing. Cell 108, 435&#226;&#8364;&#8220;438. <br /> Ernst, N.L., Panicucci, B., Carnes, J., Stuart, K., 2009. Differential functions       Maryanoff, B.E., 2004. Inhibitors serine proteases potential therapeutic agents: <br />      editosome exoUases Trypanosoma brucei. RNA 15, 947&#226;&#8364;&#8220;957.                                    road thrombin tryptase cathepsin G. J. Med. Chem. 47, 769&#226;&#8364;&#8220;787. <br /> Ernst, N.L., Panicucci, B., Igo Jr., R.P., Panigrahi, A.K., Salavati, R., Stuart, K., 2003.   McManus, M.T., Adler, B.K., Pollard, V.W., Hajduk, S.L., 2000. Trypanosoma brucei <br />      TbMP57 30 terminal uridylyl transferase (TUTase) Trypanosoma brucei               guide RNA poly(U) tail formation stabilized cognate mRNA. Mol. Cell. Biol. <br />      editosome. Mol. Cell 11, 1525&#226;&#8364;&#8220;1536.                                                           20, 883&#226;&#8364;&#8220;891. <br /> Fisk, J.C., Presnyak, V., Ammerman, M.L., Read, L.K., 2009. Distinct overlapping          McManus, M.T., Shimamura, M., Grams, J., Hajduk, S.L., 2001. Identi&#239;&#172;?cation of <br />      functions MRP1/2 RBP16 mitochondrial RNA metabolism. Mol. Cell.                     candidate mitochondrial RNA editing ligases Trypanosoma brucei. RNA 7, <br />      Biol. 29, 5214&#226;&#8364;&#8220;5225.                                                                          167&#226;&#8364;&#8220;175. <br /> Gao, G., Simpson, L., 2003. Is Trypanosoma brucei REL1 RNA ligase speci&#239;&#172;?c U-          Missel, A., Souza, A.E., Norskau, G., Goringer, H.U., 1997. Disruption gene <br />      deletion RNA editing, REL2 RNA ligase speci&#239;&#172;?c U-insertion                      encoding novel mitochondrial DEAD-box protein Trypanosoma brucei <br />      editing? J. Biol. Chem. 278, 27570&#226;&#8364;&#8220;27574.                                                     affects edited mRNAs. Mol. Cell. Biol. 17, 4895&#226;&#8364;&#8220;4903. <br /> Golas, M.M., Bohm, C., Sander, B., Effenberger, K., Brecht, M., Stark, H., Goringer,          Moazed, D., Noller, H.F., 1989. Intermediate states movement transfer RNA <br />      H.U., 2009. Snapshots RNA editing machine trypanosomes captured                  ribosome. Nature 342, 142&#226;&#8364;&#8220;148. <br />      different assembly stages vivo. EMBO J. 28, 766&#226;&#8364;&#8220;778.                                  Moshiri, H., Acoca, S., Kala, S., Najafabadi, H.S., Hogues, H., Purisima, E., Salavati, R., <br /> Guo, X., Ernst, N.L., Carnes, J., Stuart, K.D., 2010. The zinc-&#239;&#172;?ngers KREPA3                2011. Naphthalene-based RNA editing inhibitor blocks RNA editing activities and <br />      essential complete editing mitochondrial mRNAs Trypanosoma                      editosome assembly Trypanosoma brucei. J. Biol. Chem. 286, 14178&#226;&#8364;&#8220;14189. <br />      brucei. PLoS One 5, e8913.                                                               Moshiri, H., Salavati, R., 2010. A &#239;&#172;&#8218;uorescence-based reporter substrate for <br /> Guo, X., Ernst, N.L., Stuart, K.D., 2008. The KREPA3 zinc &#239;&#172;?nger motifs OB-fold                 monitoring RNA editing trypanosomatid pathogens. Nucleic Acids Res. 38, <br />      domain essential RNA editing survival Trypanosoma brucei. Mol.                 e138. <br />      Cell. Biol. 28, 6939&#226;&#8364;&#8220;6953.                                                               Muller, U.F., Goringer, H.U., 2002. Mechanism gBP21-mediated RNA/RNA <br /> Hajduk, S., Ochsenreiter, T., 2010. RNA editing kinetoplastids. RNA Biol. 7, 229&#226;&#8364;&#8220;               annealing reaction: matchmaking charge reduction. Nucleic Acids Res. 30, <br />      236.                                                                                          447&#226;&#8364;&#8220;455. <br /> Hannaert, V., Bringaud, F., Opperdoes, F.R., Michels, P.A., 2003. Evolution energy         O&#226;&#8364;&#8482;Brien, K., Matlin, A.J., Lowell, A.M., Moore, M.J., 2008. The bi&#239;&#172;&#8218;avonoid isoginkgetin <br />      metabolism compartmentation Kinetoplastida. Kinetoplastid biology                  general inhibitor Pre-mRNA splicing. J. Biol. Chem. 283, 33147&#226;&#8364;&#8220;33154. <br />      disease 2, 11.                                                                       O&#226;&#8364;&#8482;Hearn, S.F., Huang, C.E., Hemann, M., Zhelonkina, A., Sollner-Webb, B., 2003. <br /> Hashimi, H., Benkovicova, V., Cermakova, P., Lai, D.H., Horvath, A., Lukes, J., 2010.              Trypanosoma brucei RNA editing complex: band II structurally critical and <br />      The assembly F(1)F(O)-ATP synthase disrupted interference RNA                   maintains band V ligase, nonessential. Mol. Cell. Biol. 23, 7909&#226;&#8364;&#8220;7919. <br />      editing Trypanosoma brucei. Int. J. Parasitol. 40, 45&#226;&#8364;&#8220;54.                             Olliaro, P.L., Guerin, P.J., Gerstl, S., Haaskjold, A.A., Rottingen, J.A., Sundar, S., 2005. <br /> Hashimi, H., Cicova, Z., Novotna, L., Wen, Y.Z., Lukes, J., 2009. Kinetoplastid guide              Treatment options visceral leishmaniasis: systematic review clinical <br />      RNA biogenesis dependent subunits mitochondrial RNA binding                      studies India, 1980&#226;&#8364;&#8220;2004. Lancet Infect. Dis. 5, 763&#226;&#8364;&#8220;774. <br />      complex 1 mitochondrial RNA polymerase. RNA 15, 588&#226;&#8364;&#8220;599.                             Osato, D., Rogers, K., Guo, Q., Li, F., Richmond, G., Klug, F., Simpson, L., 2009. Uridine <br /> Hashimi, H., Zikova, A., Panigrahi, A.K., Stuart, K.D., Lukes, J., 2008. TbRGG1,                insertion/deletion RNA editing trypanosomatid mitochondria: search of <br />      essential protein involved kinetoplastid RNA metabolism associated                 editosome. RNA 15, 1338&#226;&#8364;&#8220;1344. <br />      novel multiprotein complex. RNA 14, 970&#226;&#8364;&#8220;980.                                      Panigrahi, A.K., Ernst, N.L., Domingo, G.J., Fleck, M., Salavati, R., Stuart, K.D., 2006. <br /> Hernandez, A., Madina, B.R., Ro, K., Wohlschlegel, J.A., Willard, B., Kinter, M.T., Cruz-          Compositionally functionally distinct editosomes Trypanosoma brucei. <br />      Reyes, J., 2010. REH2 RNA helicase kinetoplastid mitochondria:                             RNA 12, 1038&#226;&#8364;&#8220;1049. <br />      ribonucleoprotein complexes essential motifs unwinding guide                 Panigrahi, A.K., Gygi, S.P., Ernst, N.L., Igo Jr., R.P., Palazzo, S.S., Schnaufer, A., Weston, <br />      RNA (gRNA) binding. J. Biol. Chem. 285, 1220&#226;&#8364;&#8220;1228.                                            D.S., Carmean, N., Salavati, R., Aebersold, R., Stuart, K.D., 2001a. Association of <br /> Hoskins, A.A., Friedman, L.J., Gallagher, S.S., Crawford, D.J., Anderson, E.G.,                    novel proteins, TbMP52 TbMP48, Trypanosoma brucei RNA <br />      Wombacher, R., Ramirez, N., Cornish, V.W., Gelles, J., Moore, M.J., 2011.                     editing complex. Mol. Cell. Biol. 21, 380&#226;&#8364;&#8220;389. <br />      Ordered dynamic assembly single spliceosomes. Science 331, 1289&#226;&#8364;&#8220;                  Panigrahi, A.K., Schnaufer, A., Carmean, N., Igo Jr., R.P., Gygi, S.P., Ernst, N.L., Palazzo, <br />      1295.                                                                                         S.S., Weston, D.S., Aebersold, R., Salavati, R., Stuart, K.D., 2001b. Four related <br /> Huang, C.E., O&#226;&#8364;&#8482;Hearn, S.F., Sollner-Webb, B., 2002. Assembly function RNA               proteins Trypanosoma brucei RNA editing complex. Mol. Cell. Biol. 21, <br />      editing complex Trypanosoma brucei requires band III protein. Mol. Cell. Biol.             6833&#226;&#8364;&#8220;6840. <br />      22, 3194&#226;&#8364;&#8220;3203.                                                                           Panigrahi, A.K., Schnaufer, A., Ernst, N.L., Wang, B., Carmean, N., Salavati, R., Stuart, <br /> Ilag, L.L., Ng, J.H., Beste, G., Henning, S.W., 2002. Emerging high-throughput drug                K., 2003. Identi&#239;&#172;?cation novel components Trypanosoma brucei editosomes. <br />      target validation technologies. Drug Discov. Today 7, S136&#226;&#8364;&#8220;142.                               RNA 9, 484&#226;&#8364;&#8220;492. <br />  46                                         R. Salavati et al. / International Journal Parasitology: Drugs Drug Resistance 2 (2012) 36&#226;&#8364;&#8220;46 <br />  <br />  <br /> Panigrahi, A.K., Zikova, A., Dalley, R.A., Acestor, N., Ogata, Y., Anupama, A., Myler, P.J.,      Simpson, L., Aphasizhev, R., Lukes, J., Cruz-Reyes, J., 2010. Guide the <br />     Stuart, K.D., 2008. Mitochondrial complexes Trypanosoma brucei: novel                        nomenclature kinetoplastid RNA editing: proposal. Protist 161, 2&#226;&#8364;&#8220;6. <br />     complex unique oxidoreductase complex. Mol. Cell. Proteomics 7, 534&#226;&#8364;&#8220;                    Simpson, L., Sbicego, S., Aphasizhev, R., 2003. Uridine insertion/deletion RNA editing <br />     545.                                                                                              trypanosome mitochondria: complex business. RNA 9, 265&#226;&#8364;&#8220;276. <br /> Paris, Z., Hashimi, H., Lun, S., Alfonzo, J.D., Lukes, J., 2011. Futile import tRNAs       Simpson, L., Thiemann, O.H., Savill, N.J., Alfonzo, J.D., Maslov, D.A., 2000. Evolution <br />     proteins mitochondrion Trypanosoma brucei evansi. Mol. Biochem.                       RNA editing trypanosome mitochondria. Proc. Natl. Acad. Sci. USA 97, <br />     Parasitol. 176, 116&#226;&#8364;&#8220;120.                                                                          6986&#226;&#8364;&#8220;6993. <br /> Peris, M., Simpson, A.M., Grunstein, J., Liliental, J.E., Frech, G.C., Simpson, L., 1997.         Stuart, K., Allen, T.E., Heidmann, S., Seiwert, S.D., 1997. RNA editing kinetoplastid <br />     Native gel analysis ribonucleoprotein complexes Leishmania tarentolae                   protozoa. Microbiol. Mol. Biol. Rev. 61, 105&#226;&#8364;&#8220;120. <br />     mitochondrial extract. Mol. Biochem. Parasitol. 85, 9&#226;&#8364;&#8220;24.                                     Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gurtler, R.E., McKerrow, J., Reed, S., <br /> Reddy, A.S., Pati, S.P., Kumar, P.P., Pradeep, H.N., Sastry, G.N., 2007. Virtual screening            Tarleton, R., 2008. Kinetoplastids: related protozoan pathogens, different <br />     drug discovery &#226;&#8364;&#8220; computational perspective. Curr. Protein Pept. Sci. 8, 329&#226;&#8364;&#8220;                 diseases. J. Clin. Invest. 118, 1301&#226;&#8364;&#8220;1310. <br />     351.                                                                                          Stuart, K.D., Schnaufer, A., Ernst, N.L., Panigrahi, A.K., 2005. Complex management: <br /> Rogers, K., Gao, G., Simpson, L., 2007. Uridylate-speci&#239;&#172;?c 30 &#226;&#8364;&#8220;50 -exoribonucleases                    RNA editing trypanosomes. Trends Biochem. Sci. 30, 97&#226;&#8364;&#8220;105. <br />     involved uridylate-deletion RNA editing trypanosomatid mitochondria. J.                 Sturm, N.R., Simpson, L., 1990. Kinetoplast DNA minicircles encode guide RNAs for <br />     Biol. Chem. 282, 29073&#226;&#8364;&#8220;29080.                                                                     editing cytochrome oxidase subunit III mRNA. Cell 61, 879&#226;&#8364;&#8220;884. <br /> Rusche, L.N., Cruz-Reyes, J., Piller, K.J., Sollner-Webb, B., 1997. Puri&#239;&#172;?cation              Tarun Jr., S.Z., Schnaufer, A., Ernst, N.L., Proff, R., Deng, J., Hol, W., Stuart, K., 2008. <br />     functional enzymatic editing complex Trypanosoma brucei mitochondria.                        KREPA6 RNA-binding protein essential editosome integrity and <br />     EMBO J. 16, 4069&#226;&#8364;&#8220;4081.                                                                            survival Trypanosoma brucei. RNA 14, 347&#226;&#8364;&#8220;358. <br /> Rusche, L.N., Huang, C.E., Piller, K.J., Hemann, M., Wirtz, E., Sollner-Webb, B., 2001.           Teixeira, A.R., Nitz, N., Guimaro, M.C., Gomes, C., Santos-Buch, C.A., 2006. Chagas <br />     The RNA ligases Trypanosoma brucei RNA editing complex: cloning                        disease. Postgrad. Med. J. 82, 788&#226;&#8364;&#8220;798. <br />     essential band IV gene identifying band V gene. Mol. Cell. Biol. 21,              Trotter, J.R., Ernst, N.L., Carnes, J., Panicucci, B., Stuart, K., 2005. A deletion site <br />     979&#226;&#8364;&#8220;989.                                                                                          editing endonuclease Trypanosoma brucei. Mol. Cell 20, 403&#226;&#8364;&#8220;412. <br /> Salavati, R., Ernst, N.L., O&#226;&#8364;&#8482;Rear, J., Gilliam, T., Tarun Jr., S., Stuart, K., 2006. KREPA4,   Varney, M.D., Marzoni, G.P., Palmer, C.L., Deal, J.G., Webber, S., Welsh, K.M., Bacquet, <br />     RNA binding protein essential editosome integrity survival                             R.J., Bartlett, C.A., Morse, C.A., Booth, C.L., et al., 1992. Crystal-structure-based <br />     Trypanosoma brucei. RNA 12, 819&#226;&#8364;&#8220;831.                                                              design synthesis benz[cd]indole-containing inhibitors thymidylate <br /> Salavati, R., Panigrahi, A.K., Morach, B.A., Palazzo, S.S., Igo, R.P., Stuart, K., 2002.              synthase. J. Med. Chem. 35, 663&#226;&#8364;&#8220;676. <br />     Endoribonuclease activities Trypanosoma brucei mitochondria. Mol. Biochem.                 Vickerman, K., 1965. Polymorphism mitochondrial activity sleeping sickness <br />     Parasitol. 120, 23&#226;&#8364;&#8220;31.                                                                            trypanosomes. Nature 208, 762&#226;&#8364;&#8220;766. <br /> Schnaufer, A., Clark-Walker, G.D., Steinberg, A.G., Stuart, K., 2005. The F1-ATP                  von Itzstein, M., Wu, W.Y., Kok, G.B., Pegg, M.S., Dyason, J.C., Jin, B., Van Phan, T., <br />     synthase complex bloodstream stage trypanosomes unusual                             Smythe, M.L., White, H.F., Oliver, S.W., et al., 1993. Rational design potent <br />     essential function. EMBO J. 24, 4029&#226;&#8364;&#8220;4040.                                                        sialidase-based inhibitors in&#239;&#172;&#8218;uenza virus replication. Nature 363, 418&#226;&#8364;&#8220;423. <br /> Schnaufer, A., Domingo, G.J., Stuart, K., 2002. Natural induced dyskinetoplastic              Weng, J., Aphasizheva, I., Etheridge, R.D., Huang, L., Wang, X., Falick, A.M., <br />     trypanosomatids: live mitochondrial DNA. Int. J. Parasitol. 32,                    Aphasizhev, R., 2008. Guide RNA-binding complex mitochondria of <br />     1071&#226;&#8364;&#8220;1084.                                                                                        trypanosomatids. Mol. Cell 32, 198&#226;&#8364;&#8220;209. <br /> Schnaufer, A., Ernst, N.L., Palazzo, S.S., O&#226;&#8364;&#8482;Rear, J., Salavati, R., Stuart, K., 2003.            Westwell, A.D., Stevens, M.F., 2004. Hitting chemotherapy jackpot: strategy, <br />     Separate insertion deletion subcomplexes Trypanosoma brucei RNA                        productivity chemistry. Drug. Discov. Today 9, 625&#226;&#8364;&#8220;627. <br />     editing complex. Mol. Cell 12, 307&#226;&#8364;&#8220;319.                                                       WHO, 2002. WHO &#226;&#8364;&#8220; Global Burden Disease Estimates. <br /> Schnaufer, A., Panigrahi, A.K., Panicucci, B., Igo Jr., R.P., Wirtz, E., Salavati, R., Stuart,    Wilkinson, S.R., Taylor, M.C., Horn, D., Kelly, J.M., Cheeseman, I., 2008. A mechanism <br />     K., 2001. An RNA ligase essential RNA editing survival                             cross-resistance nifurtimox benznidazole trypanosomes. Proc. <br />     bloodstream form Trypanosoma brucei. Science 291, 2159&#226;&#8364;&#8220;2162.                                   Natl. Acad. Sci. USA 105, 5022&#226;&#8364;&#8220;5027. <br /> Schnaufer, A., Wu, M., Park, Y.J., Nakai, T., D <br /> </body></html>